Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion
Key facts
- Who runs it
- University Hospital Tuebingen
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 9 people enrolled
- Started
- 28 Jul 2020
- Ended
- 1 Mar 2024
- Type of study
- Interventional
- Treatments tested
- Lowering cholesterol concentrations by PCSK-9 inhibitor
- Record updated
- 16 May 2024
- Why it stopped
- poor recruitment
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures
- Medical indication for the treatment with a PCSK9-inhibitor
- HbA1c < 6,5%
Who cannot take part
- Diabetes mellitus
- Any pancreatic disease
- Hb < 11.5 g/dl (males) or Hb < 10.5 g/dl (females)
- treatment with any medication that effects on blood glucose concentrations, e.g. antidiabetic drugs or steroids
- Pregnant women or breastfeeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Dyslipidemia is characterized by low levels of HDLs, hypertriglyceridemia as well as an increases proportion of small dense LDLs. Changes in lipoprotein particles and its concentrations, especially increased levels of pro-atherogenic LDL particles play an important role in the development of cardiovascular diseases. It is well established that statin/PCSK9-inhibitor treatment is very effective in lowering LDL cholesterol levels and therefore in preventing cardiovascular events. Besides the beneficial effects on cardiovascular system, these therapies are unfortunately linked to increased risk for type 2 diabetes.
Read full original descriptionShow less
However underlying mechanisms for the association between LDL cholesterol levels and the risk for type 2 diabetes remains largely unknown.Type 2 diabetes is especially characterized by insulin resistance and impaired insulin secretion from pancreatic beta-cells. Insulin resistance alone is insufficient to cause type 2 diabetes, as long as the ß-cell is able to compensate for the increased demand for insulin. Once this compensatory mechanism reaches its physiological limits, individuals progress to type 2 diabetes. Accordingly we aimed to investigate the associations between LDL cholesterol concentrations and the key issue in the pathogenesis of type 2 diabetes, insulin secretion before and after lowering cholesterol concentration by treatment with Evolocumab for 12 weeks in patients with medical indication for a treatment with a PCSK9-inhibitor. Therefore, patients will either undergo a hyperglycemic clamp or a oral glucose tolerance test in randomized manner.
The group in the trial
- LDL lowering therapyTreatment being tested
Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
Treatment: Lowering cholesterol concentrations by PCSK-9 inhibitor
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 May 2024